Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation

Blood

Volumn 113, Issue 24, 2009, Pages 6148-6152

  Smith, Corey ^a   Wakisaka, Naohiro ^b   Crough, Tania ^a   Peet, Jesse ^a   Yoshizaki, Tomokazu ^b   Beagley, Leone ^a   Khanna, Rajiv ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; EPITOPE; HLA A2 ANTIGEN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LATENT MEMBRANE PROTEIN 2A; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUTANT PROTEIN; UNCLASSIFIED DRUG; EBNA 3A ANTIGEN; EBNA-3A ANTIGEN; EBV ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN BARR VIRUS; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; EPSTEIN BARR VIRUS ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; MATRIX PROTEIN; PEPTIDE FRAGMENT; PROTEASOME;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CIS TRANS ISOMERISM; CONTROLLED STUDY; EFFECTOR CELL; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; UPREGULATION; VIRUS ONCOGENE; B CELL LYMPHOMA; CELL LINE; FEMALE; FLOW CYTOMETRY; GENETICS; IMMUNOLOGY; METABOLISM; NASOPHARYNX TUMOR; PATHOLOGY; PROTEIN MULTIMERIZATION; TUMOR CELL CULTURE; UTERINE CERVIX TUMOR; VACCINIA VIRUS; VIRUS INFECTION;

ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; EPITOPES, T-LYMPHOCYTE; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON-GAMMA; LYMPHOMA, B-CELL; NASOPHARYNGEAL NEOPLASMS; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN MULTIMERIZATION; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; VACCINIA VIRUS; VIRAL MATRIX PROTEINS;

EID: 67650394808     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-02-203687     Document Type: Article

References (25)

1. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000;54:19-48. (Pubitemid 30835905)
2. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76-98.
3. Rowe M, Khanna R, Jacob CA, et al. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinated up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol. 1995;25:1374-1384.
4. Burrows JM, Burrows SR, Poulsen LM, Sculley TB, Moss DJ, Khanna R. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol. 1996;70:2490-2496. (Pubitemid 26087614)
5. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol. 2000;18:861-926.
6. Khanna R, Moss DJ, Gandhi M. Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies. Nat Clin Pract Oncol. 2005;2:138-149. (Pubitemid 40823165)
7. Izumi KM, Kaye KM, Kieff ED. The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1997;94: 1447-1452.
8. Pai S, O'Sullivan BJ, Cooper L, Thomas R, Khanna R. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells. J Virol. 2002;76:1914-1921. (Pubitemid 34094638)
9. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLAA2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol. 1998;28:451-458. (Pubitemid 28101719)
10. Duraiswamy J, Burrows JM, Bharadwaj M, et al. Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions. J Virol. 2003;77:7401-7410. (Pubitemid 36734509)
11. Anderson K, Cresswell P, Gammon M, Hermes J, Williamson A, Zweerink H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J Exp Med. 1991;174:489-492.
12. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol. 1997;71:586-594. (Pubitemid 26412329)
13. Cheung ST, Huang DP, Hui AB, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer. 1999; 83:121-126.
14. Elkington R, Walker S, Crough T, et al. Ex vivo profiling of CD8+-T-cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol. 2003; 77:5226-5240. (Pubitemid 36460937)
15. Khanna R, Burrows SR, Kurilla MG, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992;176: 169-176.
16. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997; 16:6478-6485. (Pubitemid 27483273)
17. Martin J, Sugden B. Transformation by the oncogenic latent membrane protein correlates with its rapid turnover, membrane localization, and cytoskeletal association. J Virol. 1991;65:3246-3258.
18. Webb N, Connolly G, Tellam J, Yap AS, Khanna R. Epstein-Barr virus associated modulation of Wnt pathway is not dependent on latent membrane protein-1. PLoS ONE. 2008;3:e3254.
19. Smith C, Cooper L, Burgess M, et al. Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol. 2006;177:4897-4906. (Pubitemid 44469826)
20. Zhong J, Rist M, Cooper L, Smith C, Khanna R. Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS ONE. 2008;3:e3256.
21. Dukers DF, Meij P, Vervoort MB, et al. Direct immunosuppressive effects of EBV-encoded latent membrane protein 1. J Immunol. 2000;165:663-670. (Pubitemid 30484731)
22. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905-1912.
23. Gavioli R, Vertuani S, Masucci MG. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors. Int J Cancer. 2002;101:532-538.
24. Anton LC, Snyder HL, Bennink JR, et al. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J Immunol. 1998; 160:4859-4868.
25. Wherry EJ, Golovina TN, Morrison SE, et al. Re-evaluating the generation of a "proteasome-independent" MHC class I-restricted CD8 T cell epitope. J Immunol. 2006;176:2249-2261.